In another study with a larger sample, dacomitinib (PF-00299804) vs erlotinib in the treatment of advanced NSCLC (ARCHER 1009, ClinicalTrials.gov identifier: NCT01360554)[21] reported that 8 of 436 (1.83%) cases presented with mild and moderate ALT increased, 10 of 436 (2.29%) cases with mild and moderate AST increased in dacomitinib group, and there was 1 case with hyperbilirubinemia. This evidence concerns the gene GPT and Hyperbilirubinemia.